Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ABEO | US
0.25
5.13%
Healthcare
Biotechnology
30/06/2024
09/04/2026
5.12
4.82
5.25
4.82
Abeona Therapeutics Inc. a clinical-stage biopharmaceutical company develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101 an autologous engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York New York.
View LessStrength based on increasing price with high volume
Low Debt to Asset (< 0.2)
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
47.8%1 month
47.9%3 months
44.0%6 months
55.6%-
-
3.99
0.32
0.17
-0.58
53.29
-
-54.75M
221.77M
221.77M
-
-
-
-100.00
-127.38
11.83
6.35
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.02
Range1M
1.09
Range3M
1.46
Rel. volume
1.37
Price X volume
10.10M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated | PRLD | Biotechnology | 4.4 | 242.11M | 4.27% | n/a | 9.99% |
| Editas Medicine Inc | EDIT | Biotechnology | 2.89 | 238.36M | 4.71% | n/a | 16.68% |
| Alector Inc | ALEC | Biotechnology | 2.4 | 233.57M | -0.83% | n/a | 23.98% |
| Anika Therapeutics Inc | ANIK | Biotechnology | 15.22 | 225.21M | 0.07% | n/a | 13.35% |
| Verastem Inc | VSTM | Biotechnology | 5.59 | 224.96M | 2.57% | n/a | 104.63% |
| Arcturus Therapeutics Ltd | ARCT | Biotechnology | 8.22 | 222.29M | -3.29% | n/a | 11.94% |
| Compugen Ltd | CGEN | Biotechnology | 2.48 | 222.05M | 8.30% | n/a | 5.19% |
| BioAtla Inc. | BCAB | Biotechnology | 4.52 | 218.48M | 1.80% | n/a | 5.30% |
| LogicBio Therapeutics Inc | LOGC | Biotechnology | 8.26 | 217.03M | -0.60% | n/a | 0.00% |
| Voyager Therapeutics Inc | VYGR | Biotechnology | 3.96 | 215.95M | 1.02% | 29.89 | 13.99% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CPI Card Group Inc | PMTS | Building Products & Equipment | 17.04 | 190.13M | 2.90% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 10.17 | 163.30M | 1.09% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.1 | 97.93M | -1.76% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 5.52 | 89.92M | -2.82% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.62 | 72.76M | -1.53% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.55 | 64.11M | 4.41% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.16 | 16.95M | -4.13% | 0.03 | 16.03% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 11.02 | 16.78M | 94.36% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.651 | 12.58M | -0.82% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.3 | 3.32M | 2.85% | n/a | 17.32% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.58 | - | Cheaper |
| Ent. to Revenue | 53.29 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.99 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 43.99 | - | Lower Risk |
| Debt to Equity | 0.32 | -1.23 | Expensive |
| Debt to Assets | 0.17 | 0.25 | Cheaper |
| Market Cap | 221.77M | - | Emerging |